Covid-19 vaccine had robust immune response in Phase 1 trial: Bharat Biotech
NEW DELHI: The interim findings of phase 1 clinical trial of Covid-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events. The vaccine induced robust binding and neutralising antibody responses which were comparable to those […]